Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 1315853.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Serum neutralizing, nasopharyngeal neutralizing, and IgA antibodies to polioviruses 1, 2, and 3 were detected in preterm and term infants who had received three doses of an enhanced-potency inactivated poliovirus vaccine at 2, 4, and 12 months of age. After the third dose of this vaccine, 95% or more of the infants tested had detectable serum neutralizing antibodies to polioviruses types 1, 2, and 3. Nasopharyngeal neutralizing and IgA antibodies were detected in 43% to 91% of the infants. The peak geometric mean titers of serum and nasopharyngeal antibodies against polioviruses types 1, 2, and 3 were similar for both groups. These preliminary data indicate that preterm infants are capable of mounting systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine that are comparable to those made by term infants.
Medical subject headings
- Antibodies, Viral
- Infant, Premature
- Poliomyelitis
- Poliovirus
- Poliovirus Vaccine, Inactivated
- Vaccination